CAMBRIDGE, Mass., September 12, 2022 (GLOBE NEWSWIRE) — Codiak BioSciences, Inc. CDAK (“Codiak”), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of drugs, today announced pricing for its underwritten public offering of 13,333,333 common shares and accompanying purchase warrants of 13,333,333 shares known of common stock at a combined public offering price of $1.50 per share, together with accompanying warrants, for gross proceeds of approximately $20 million, before deduction of underwriting rebates and commissions and offering expenses. All securities are offered by Codiak. The warrants have an exercise price of $1.875 per share, are exercisable immediately and will expire five years from the date of issuance. In addition, Codiak has granted the underwriters a 30-day option to purchase up to an additional 1,999,999 common shares and accompanying warrants to purchase 1,999,999 common shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on September 15, 2022, subject to customary closing conditions.

Jefferies is acting as sole book-running manager for the offering.

The securities are being offered by Codiak pursuant to a shelf registration statement on Form S-3 (File Number 333-260781) previously filed with the Securities and Exchange Commission (the “SEC”) and effective November 15, 2021. A preliminary prospectus supplement in Reference to the offering has been filed with the SEC and a final prospectus supplement relating to the offering will be filed with the SEC. If available, copies of the final prospectus supplement and the accompanying prospectus relating to such securities may be obtained at the SEC’s website at http://www.sec.gov or contact Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY…

[ad_2]

Source story